DUBLIN, June 14, 2021 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Nothing Small About It (www.nothingsmallaboutit.com), an online program developed in consultation with leading cancer organizations CancerConcern, GO2 Foundation for Lung Cancer, Lung Cancer Foundation of America and LUNGevity Foundation. Nothing Small About It is the first digital hub for a U.S. audience dedicated solely to patients and caregivers with small cell lung cancer (SCLC), providing easy-to-use content that puts real people and their stories at the center of the experience, enabling people with SCLC to become informed advocates in their health and well-being.
🎬📺 Free Movies and Free TV Shows! 🎭🎬
“Our research found that people living with small cell lung cancer and their caregivers tend to feel lost within the wider lung cancer community, and they often experience feelings of stigma, fear and hopelessness due to the devastating nature of the disease,” said Abizer Gaslightwala , vice president, chief of American hematology and oncology at Jazz Pharmaceuticals. “This insight led us to partner with leading cancer organizations to create a resource that covers the full emotional needs of people with SCLC and their loved ones. That’s why we developed Nothing Small About It – to address the challenges that arise. At every stage, we’re trying to make diagnosis humane by raising awareness of patients’ and caregivers’ experiences, so that we can, in turn, show empathy and increase feelings of self-esteem for those living with the disease — both patients and caregivers.”
Nothing Small About It takes a user-friendly approach to SCLC awareness by providing patients and caregivers with information to manage SCLC at each stage of diagnosis, while also establishing connections with trusted resources available in the wider cancer community. Through the development and evolution of Nothing Small About It, Jazz strives to provide more personalized support across the continuum of SCLC care while inspiring patients and caregivers to take an active role in their health and wellness.
“As rapid and exciting progress is made in the treatment of small cell lung cancer, we will work with our partners to mobilize substantial resources towards the goal of ensuring that patients and their caregivers are identified and engaged in a consistent and meaningful way. ,” said Laurie Fenton Ambrose, co-founder, president and CEO of GO2 Foundation. “The different types of support and services will be aligned to best meet people where they are, and Nothing Small About It is an excellent example of a collaborative initiative that can help stakeholders achieve our common goal of supporting the SCLC community .”
Nothing Small About It greets viewers with an emotionally resonant video titled “More Than 10 Minutes,” which allows SCLC patients and their loved ones to hear how others have coped with a diagnosis, news of progression, and other challenges along the way. Viewers then have the opportunity for an interactive experience that points them in the right direction for finding resources and support no matter where they are physically or mentally in their individual cancer journeys.
“The most helpful thing to me when I was diagnosed with small cell lung cancer 14 years ago was doing research and reaching out to advocacy groups so I could educate myself about my diagnosis,” said Montessa Lee, an advocate for people living with SCLC and a valued participant in the Nothing Small About It program. “I want other people going through small cell lung cancer to know that your life doesn’t stop here, and while you may have to take a journey from time to time that may be tough, with the right support you can get through it.”
With unique content tailored to both patients and caregivers, Nothing Small About It allows users to delve deeper into topics such as building a support network, considerations to keep in mind when choosing a treatment plan, and tips for maintaining emotional and physical well-being, among many others.
Nothing Small About It is available to US patients and caregivers who want to learn more about SCLC and how to find support. Visit www.nothingsmallaboutit.com start.
About small cell lung cancer
In the US, about 13 percent of lung cancers are small cell. About 30,000 to 35,000 new cases of small cell lung cancer (SCLC) are reported in the US each year.1.2 The risk of developing SCLC is much higher in current or former tobacco smokers; However, SCLC can also be caused by exposure to secondhand smoke, asbestos, some inhaled chemicals, radiation, and air pollution. People with a family history of lung cancer may also be at higher risk.3 SCLC is the most aggressive form of lung cancer and tends to spread quickly to other parts of the body, including the brain, liver, and bones.4.5 A large percentage of SCLC patients on treatment achieve a transient response, although the cancer often recures and is usually more aggressive and resistant to previously effective regimens.2
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company focused on innovating to change the lives of patients and their families. We are committed to developing life-changing medicines for people with serious illnesses – often with limited or no therapeutic options. We have a diverse portfolio of marketed drugs and new product candidates, from early to late stages of development, in neuroscience and oncology. We are actively exploring new options for patients, including new compounds, small molecules and biologics, and through cannabinoid science and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the world serving patients in nearly 75 countries. For more information, visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
About the GO2 Lung Cancer Foundation
Founded by patients and survivors, GO2 Lung Cancer Foundation transforms survivorship as the world’s leading organization committed to saving, extending and improving the lives of those who are vulnerable, at risk and diagnosed with lung cancer. The GO2 Foundation helps and listens to people living with and at risk for lung cancer to reduce stigma, improve quality of life and increase survival. They empower the community by helping people navigate the paths of early detection, diagnosis and treatment. Insights help the GO2 Foundation improve care, raise awareness, drive advocacy and lead research with a vision to triple the number of survivors in the next decade. For more information visit https://go2foundation.org.
Vice President, Corporate Affairs
Jazz Pharmaceuticals plc
Ireland, +353 1 697 2141
USA +1 215 867 4910
Contact for investors:
Andrea N. Flynn, Ph.D.
Vice President, Head of Investor Relations
Jazz Pharmaceuticals plc
Ireland, +353 1 634 3211
- American Cancer Society. Key statistics for lung cancer. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html. Updated January 12, 2021. Enter June 11, 2021.
- National Organization for Rare Diseases. Small cell lung cancer. https://rarediseases.org/rare-diseases/small-cell-lung-cancer/. Updated 2019. Entered June 11, 2021.
- American Cancer Society. Small cell lung cancer causes, risk factors and prevention. https://www.cancer.org/content/dam/CRC/PDF/Public/8709.00.pdf. Updated May 16, 2016. Enter June 11, 2021.
- American Cancer Society. What is Lung Cancer? https://www.cancer.org/cancer/long-cancer/about/what-is.html. Updated October 1, 2019. Enter June 11, 2021.
- American Cancer Society. Stages of small cell lung cancer. https://www.cancer.org/cancer/long-cancer/detection-diagnosis-staging/staging-sclc.html. Updated October 1, 2019. Enter June 11, 2021.
SOURCE Jazz Pharmaceuticals plc